Antonio Wolff's guest appearances

Antonio Wolff

Investigating Breast Cancer

2012 San Antonio Breast Cancer Symposium (SABCS)

Robert Schneider

Walter Willett

Michael Clarke

Peter Kaufman

Mark Robson

James Evans

Mina Bissell

Lawrence Shulman

Robert Coleman

Clifford Hudis

Larry Norton

Jack Cuzick

Luca Gianni

Alan Ashworth

David Rimm

OwlTail

 In the fight to understand and solve breast cancer, “it takes a village.” In this case, the village is more like a globally connected series of research labs, scientists, patients, funders and more. In other words, something that looks a lot like the Translational Breast Cancer Research Consortium (TBCRC). The TBCRC is a collaborative group founded in 2005 to conduct innovative and high-impact clinical trials for breast cancer led by Dr. Antonio Wolff. Dr. Wolff, a BCRF investigator since 2007, is the Chief Operating Officer for the Translational Breast Cancer Research Consortium (TBCRC).

In the fight to understand and solve breast cancer, “it takes a village.” In this case, the village is more like a globally connected series of research labs, scientists, patients, funders and more. In other words, something that looks a lot like the Translational Breast Cancer Research Consortium (TBCRC). The TBCRC is a collaborative group founded in 2005 to conduct innovative and high-impact clinical trials for breast cancer led by Dr. Antonio Wolff.  Dr. Wolff, a BCRF investigator since 2007, is the Chief Operating Officer for the Translational Breast Cancer Research Consortium (TBCRC).

A Cross-disciplinary Approach to Breast Cancer Research with Dr. Antonio Wolff

Johns Hopkins

Prof Antonio Wolff talks to ecancer at SABCS 2012 about the the National Comprehensive Cancer Network (NCCN) study on the diagnosis of blood cancer in women who have already been diagnosed with breast cancer. The study looked at cooperative group trials and institutional series reported the risk of MDS and/or AML after adjuvant chemotherapy for early stage breast cancer and examined the incidence of MDS and/or AML in breast cancer survivors.

Prof Antonio Wolff talks to ecancer at SABCS 2012 about the the National Comprehensive Cancer Network (NCCN) study on the diagnosis of blood cancer in women who have already been diagnosed with breast cancer. The study looked at cooperative group trials and institutional series reported the risk of MDS and/or AML after adjuvant chemotherapy for early stage breast cancer and examined the incidence of MDS and/or AML in breast cancer survivors.

Diagnosis of blood cancer after a breast cancer diagnosis: Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA